Spots Global Cancer Trial Database for MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Official Title: MTH1, A Phase I, Study on Tumors Inhibition, First in Human, First in Class
Study ID: NCT03036228
Conditions
Interventions
Study Description
Brief Summary: Primary Objective • To determine the safety and tolerability of Karonudib (TH1579) in escalating doses for the treatment of patients with advanced solid malignant tumours. Secondary Objective * To define DLT and MTD. * To determine a recommended phase 2 dose (RP2D) and schedule. * To determine the pharmacokinetics of Karonudib. * To determine preliminary signs of clinical efficacy of Karonudib. * To determine overall survival.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Karolinska University Hospital, Stockholm, , Sweden
Contact Details
Name: Teresa Sandvall, MSc
Affiliation: Oxcia
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
